The record
Written from the 1 report below. Nothing here is unsourced.
- Dolat Capital has downgraded Dr. Reddy's Laboratories' stock and cut its target price after the company's first quarter results.
- The quarter included a provision of Rs 240 crore towards inventory and other associated costs related to Semaglutide API.
- This matters because the brokerage's rating change signals reduced confidence in the stock following the provision-related hit.
What to watch next
- Impact of the Semaglutide API provision on upcoming quarters' margins
- Any management commentary or clarification on Semaglutide API-related costs
- Whether other brokerages follow with similar rating actions on Dr. Reddy's
Coverage1
1 report
English national1
All filed from India
Named India · Dr Reddy's · Dolat Capital · Semaglutide API
The 1 report is listed beside the record.
Ask this story
Answers cite the reports above, or say they can't.